Stock BBZA BB BIOTECH AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials BB Biotech AG Xetra

Equities

BBZA

CH0038389992

Biotechnology & Medical Research

Market Closed - Xetra
Other stock markets
 11:35:50 2024-07-12 am EDT 		5-day change 1st Jan Change
43.3 EUR -0.23% Intraday chart for BB Biotech AG +4.97% -4.84%
Apr. 27 Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
Apr. 26 Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,670 4,108 4,274 3,027 2,345 2,325 - -
Enterprise Value (EV) 1 3,790 209.4 4,626 3,389 2,649 2,626 2,658 2,624
P/E ratio 5.42 x 5.94 x -10.6 x -8.49 x -11.3 x 11 x 10 x 8.62 x
Yield 5.13% 4.86% 4.99% 5.16% 4.68% 5.21% 5.31% 5.4%
Capitalization / Revenue 5.04 x 5.54 x 1,068,528 x -9.63 x -14.1 x 9.34 x 8.66 x 7.6 x
EV / Revenue 5.2 x 0.28 x 1,156,569 x -10.8 x -15.9 x 10.5 x 9.9 x 8.57 x
EV / EBITDA 5.57 x 0.3 x -11.5 x -9.48 x -13.2 x 12.1 x 15.8 x 9.55 x
EV / FCF 17.6 x 0.8 x -48.8 x 14.7 x 12.1 x 19.7 x 11.5 x -
FCF Yield 5.67% 125% -2.05% 6.82% 8.24% 5.08% 8.72% -
Price to Book 1.08 x 1.05 x 1.3 x 1.13 x 1.01 x 0.96 x 0.92 x 0.87 x
Nbr of stocks (in thousands) 55,400 55,400 55,400 54,846 54,846 54,846 - -
Reference price 2 66.25 74.15 77.15 55.20 42.75 42.40 42.40 42.40
Announcement Date 2/21/20 2/19/21 2/18/22 2/17/23 2/16/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 728.2 741.8 0.004 -314.3 -166.6 249 268.5 306.1
EBITDA 1 679.9 694 -402.8 -357.3 -201.3 217.8 168.6 274.9
EBIT 1 678.7 692.1 -403.8 -357.3 -201.3 217.8 168.6 274.9
Operating Margin 93.21% 93.31% -10,093,875% 113.69% 120.79% 87.47% 62.81% 89.81%
Earnings before Tax (EBT) 1 677.5 691.2 -404.7 -357.8 -206.5 212.5 232 269.6
Net income 1 677.4 691.2 -404.8 -358 -206.6 212.5 166 269.6
Net margin 93.03% 93.18% -10,120,200% 113.92% 124% 85.34% 61.82% 88.08%
EPS 2 12.23 12.48 -7.310 -6.500 -3.770 3.870 4.230 4.920
Free Cash Flow 1 215 262.4 -94.79 231.1 218.3 133.5 231.9 -
FCF margin 29.53% 35.38% -2,369,675% -73.55% -131.01% 53.61% 86.37% -
FCF Conversion (EBITDA) 31.62% 37.82% - - - 61.29% 137.5% -
FCF Conversion (Net income) 31.74% 37.97% - - - 62.82% 139.7% -
Dividend per Share 2 3.400 3.600 3.850 2.850 2.000 2.210 2.250 2.290
Announcement Date 2/21/20 2/19/21 2/18/22 2/17/23 2/16/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2
Net sales - -
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income 1 -299.9 -233.1
Net margin - -
EPS -5.430 -
Dividend per Share - -
Announcement Date 4/22/22 7/22/22
1CHF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 119 - 352 361 304 301 333 299
Net Cash position 1 - 3,898 - - - - - -
Leverage (Debt/EBITDA) 0.1755 x - -0.8743 x -1.011 x -1.512 x 1.382 x 1.975 x 1.088 x
Free Cash Flow 1 215 262 -94.8 231 218 134 232 -
ROE (net income / shareholders' equity) 21.6% 19% -11.3% -12% -8.25% 3.7% 4.1% -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 61.30 70.30 59.30 49.00 42.40 44.00 46.00 48.60
Cash Flow per Share - - - - - - - -
Capex - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 2/21/20 2/19/21 2/18/22 2/17/23 2/16/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
42.4 CHF
Average target price
47.7 CHF
Spread / Average Target
+12.50%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.45% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BION Stock
  4. BBZA Stock
  5. Financials BB Biotech AG